Compare Jabil Inc (JBL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Recursion Pharmaceuticals Inc — how do they compare? Jabil Inc trades at $303.26 (market cap $31.35B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Jabil Inc is far larger — about 14.6× Recursion Pharmaceuticals Inc's market cap, and Jabil Inc pays a 0.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JBL | RXRX | |
|---|---|---|
Market Cap | $31.35B | $2.14B |
Volume | 1,337,978 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $385.50 | $6.79 |
52-Week Low | $192.49 | $2.84 |
Typical Hold Time | 23 Days | 22 Days |
Enterprise Value | $33.63B | $1.66B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.47, down 3.14% amid bearish technical signals despite strong Q4 2026 earnings that beat estimates with EPS of $4.40 versus $4.07 expected. The stock shows neutral oscillators but bearish moving averages, with support at $296 and resistance at $303. Revenue grew to $29.80B in 2025 with net income of $657M, while 2026 projections indicate $36.0B revenue and $1.0B net income, supported by AI infrastructure demand.
Outlook remains positive with 60.87% analyst buy ratings and a $434.75 consensus price target implying 45% upside. Key risks include high debt levels and market volatility, but strong earnings momentum and AI-driven growth in fiscal 2027 provide investment opportunity. Monitor execution against guidance and macroeconomic conditions.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
